Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

us.

---------------------------------

(1) Cell, 2 November 2007, ANTI-PlGF INHIBITS GROWTH OF VEGF(R)-INHIBITOR RESISTANT TUMORS WITHOUT AFFECTING HEALTHY VESSELS - Christian Fischer, Bart Jonckx, Massimiliano Mazzone, Serena Zacchigna, Monica Autiero, Emmanuel Chorianopoulos, Marta Koch, Maria Demol, Sabine Wyns, Lucia Pattarini, Nico van Rooijen, Stephane Plaisance, Mauro Giacca, Mieke Dewerchin, Lieve Moons, Jean Marie Stassen, Desire Collen & Peter Carmeliet

For further information please contact:

ThromboGenics:

Prof. Desire Collen, Tel: +32(0)16-34-61-94;

Dr. Patrik De Haes, Fax +32(0)16-34-61-34.

Citigate Dewe Rogerson:

Sylvie Berrebi / Amber Bielecka / David Dible,

Tel: +44(0)207-638-95-71,

Mobile: +44(0)7767-771-533.


'/>"/>
SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Tetrahedral dice, which have four triangular sides, pack ... to research performed by a collaboration of New York ... result of a series of experiments that involved pouring ... dice until the containers were completely filled. After adding ...
... 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ( ANPI, TSX: ANP), a specialty ... exclusive distribution agreement with B. Braun for its proprietary Quill(TM) SRS product line ... The term of the distribution agreement will be for five years. , ... According to The Royal College of Surgeons ...
... , LAWRENCEVILLE, N.J. , May 3 ... (n = 520) multi-center patient registry study of its Lacrisert® ... index (OSDI) in patients with moderate-to-severe dry eye after one ... poster this week during the 2010 Annual Meeting of the ...
Cached Biology Technology:Densest dice packing and computing with molecules 2Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line 2Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line 3Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line 4Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line 5Study of Lacrisert(R) Dry Eye Insert 2Study of Lacrisert(R) Dry Eye Insert 3Study of Lacrisert(R) Dry Eye Insert 4Study of Lacrisert(R) Dry Eye Insert 5
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... Tall fescue toxicosis is one of the most ... no cure for this costly disorder, there are proven ... new professional guide, Tall Fescue Toxicosis and Management is ... want to better understand and control toxicosis. "We ...
... NY, June 15 Robert H. Wurtz, PhD, a pioneer ... of the 2010 Neuroscience Prize of The Peter and Patricia ... information and controls eye movements laid the groundwork for subsequent ... led scientists to a deeper understanding of how the brain ...
... of dedicated South Florida researchers from the University of ... and the National Oceanic and Atmospheric Administration,s Atlantic Oceanographic ... whether oil was, as predicted, being pulled into the ... The University of Miami,s 96-foot catamaran ...
Cached Biology News:Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 2Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 3Scientists locate oil plume extending toward Dry Tortugas 2Scientists locate oil plume extending toward Dry Tortugas 3
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Normal sheep serum collected from healthy normal sheep...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Pooled normal sreum with 0.1% sodium azide as preservative...
Biology Products: